©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 6, 2024; 12(16): 2686-2691
Published online Jun 6, 2024. doi: 10.12998/wjcc.v12.i16.2686
Published online Jun 6, 2024. doi: 10.12998/wjcc.v12.i16.2686
Antifungal pipeline: Is there light at the end of the tunnel?
Georgios Schinas, Karolina Akinosoglou, Department of Medicine, University of Patras, Patras 26504, Greece
Nikolaos Spernovasilis, Department of Infectious Diseases, German Oncology Center, Limassol 4108, Cyprus
Author contributions: Schinas G, Spernovasilis N and Akinosoglou K contributed to the review of literature, writing and editing of the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest.
Corresponding author: Nikolaos Spernovasilis, BSc, MD, MSc, PhD, Director, Department of Infectious Diseases, German Oncology Center, Nikis 1, Limassol 4108, Cyprus.
Received: December 11, 2023
Revised: March 19, 2024
Accepted: April 19, 2024
Published online: June 6, 2024
Processing time: 169 Days and 15.7 Hours
Revised: March 19, 2024
Accepted: April 19, 2024
Published online: June 6, 2024
Processing time: 169 Days and 15.7 Hours
Core Tip
Core Tip: The landscape of antifungal therapy has long been dominated by a handful of drug classes, namely azoles, polyenes, and echinocandins. Issues such as the development of resistance/tolerance, interactions and inherent toxicity, and narrow spectrum of activity have limited their therapeutic utility to clinicians. All these limitations underline the urgent need for novel approaches, with the pipeline for new antifungals having been relatively dry for about 30 years. Thankfully, the pharmaceutical landscape has recently shown promising signs of innovation regarding antifungal agents.